Skip to content

Alumis Inc. ALMS Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Amgen logo
AmgenAMGN
$9.19B+48.1%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$486.72M+33.4%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$456.23M-35.1%
Vera Therapeutics logo
Vera TherapeuticsVERA
$499.7M-6.6%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.2B+266%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s total equity?
Alumis Inc. (ALMS) reported total equity of $567.02M in Q1 2026.
How has Alumis Inc.'s total equity changed year-over-year?
Alumis Inc.'s total equity increased by 236.9% year-over-year, from $168.31M to $567.02M.
What is the long-term trend for Alumis Inc.'s total equity?
Over 3 years (2022 to 2025), Alumis Inc.'s total equity has grown at a 15.6% compound annual growth rate (CAGR), from -$195.24M to $301.3M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.